Metastatic Castration-Sensitive Prostate Cancer

Research by Fillmore and his collaborators focuses on optimizing systemic therapy for patients with metastatic castration-sensitive prostate cancer. Through a nationwide analysis of Veterans Affairs data, he demonstrated that abiraterone and enzalutamide provide comparable overall survival and treatment durability. His findings further indicate that enzalutamide may offer a modest survival advantage specifically for patients aged 75 years and older.